VU Research Portal
Bones in balance
Vlot, M.C.
2020
document version
Publisher's PDF, also known as Version of record
Link to publication in VU Research Portal
citation for published version (APA)
Vlot, M. C. (2020). Bones in balance: use of bone turnover markers in clinical practice.
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights. • Users may download and print one copy of any publication from the public portal for the purpose of private study or research. • You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal ?
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.
E-mail address:
vuresearchportal.ub@vu.nl
Table of Contents
Part I IntroductionChapter 1 General introduction 13
Chapter 2 Clinical utility of bone markers in various diseases 25
Part II Effects of sex steroids on bone health in transgender persons
Chapter 3 Effect of pubertal suppression and cross-sex hormone therapy on 57 bone turnover markers and bone mineral apparent density (BMAD) in
transgender adolescents
Chapter 4 Bone mineral density increases in trans persons after 1 year of 77 hormonal treatment: a multicenter prospective observational study
Chapter 5 Gender-affirming hormone treatment decreases bone turnover in 95 trans women and older trans men
Part III Effects of inflammation and auto-immune disease on bone turnover
Chapter 6 Effect of antiretroviral therapy on bone turnover and bone mineral 117 density in men with primary HIV-1 infection
Chapter 7 Multiple sclerosis patients show lower bioavailable 25(OH)D and 131
1,25(OH)2D, but no difference in ratio of 25(OH)D/24,25(OH)2D and
FGF23 concentrations
Part IV Possible role of FGF23 as tumor marker in malignant disease
Chapter 8 Plasma FGF23 is not elevated in prostate cancer 153
Part V Summary and discussion
Chapter 9 Summary and discussion (English and Dutch) 163
Part VI Appendices
List of publications 185
Contributing authors and affiliations 187
Portfolio 190
About the author 194